title: Complete remission of platinium refractory ovarian cancer with second line tegafur with uracil monotherapy: a case report.
abstract: BACKGROUND
  Ovarian cancer remains one of the most lethal of all gynecologic malignancies, accounting for more deaths than cervical and uterine cancer combined. Advanced ovarian cancer is a chemosensitive tumor and most patients initially respond to platinum-based combination chemotherapy with response rates of about 70%, including a high proportion of complete responses. However, despite aggressive surgery and chemotherapy, more than 80% of patients will relapse and will then be treated with second line chemotherapy with objective responses in about 20% of patients and even lower percentages of complete responses.
  
  
  METHODS
  We observed a 42-months of complete response with administration of 1-[2-tetrahydrofuryl]-5-fluorouracil mixed with uracil (UFT) in patient with platinium refractory ovarian cancer.
  
  
  CONCLUSIONS
  We report a complete remission of platinium refractory epithelial ovarian cancer with UFT monotherapy that was not reported previously.
authors.affiliation: Department of Medical Oncology, Gaziantep Oncology Hospital, School of Medicine, Gaziantep University, Gaziantep, Turkey.
authors.forename: Celalettin
authors.initials: C
authors.lastname: Camci
authors.forename: Alper
authors.initials: A
authors.lastname: Sevinc
authors.forename: Yilmaz
authors.initials: Y
authors.lastname: Aslan
authors.forename: Mehmet Emin
authors.initials: ME
authors.lastname: Kalender
authors.forename: Suleyman
authors.initials: S
authors.lastname: Buyukberber
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002291:Carcinoma, Papillary / Q000188:drug therapy / Q000556:secondary / Q000601:surgery; D003131:Combined Modality Therapy; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy / Q000556:secondary / Q000601:surgery; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D011379:Prognosis; D012074:Remission Induction; D016879:Salvage Therapy; D005641:Tegafur / Q000008:administration & dosage; D016896:Treatment Outcome; D014498:Uracil / Q000008:administration & dosage
chemical_list: D005641:Tegafur; D014498:Uracil